Asia
Amgen and Kirin have decided to dissolve their joint venture, Kirin-Amgen.
Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.
Fosun Pharma said it would buy Tridem Pharma S.A.S. for $73M, in a move to expand its market share in Europe and Africa.
Suzhou’s MabSpace Biosciences filed an IND application with the CFDA last month to begin human testing of a second-generation PD-L1 antibody.
Teva said Lilly’s planned drug would infringe five patents that cover its own migraine drug, which it sought U.S. Food and Drug Administration approval for on Oct. 16.
Tianjin CanSino Biologics announced CFDA approval of its Ebola virus vaccine for China.
WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage.
GIMDx of Carlsbad, California acquired exclusive China OEM and distribution rights to oncology diagnostic products made by IncellDx, a Menlo Park company.
WuXi AppTec will acquire a global clinical-stage contract research company, ResearchPoint Global, of Austin, Texas.
Prenetics Limited raised $40 million to expand its pan-Asia DNA testing service aimed at individuals.
PRESS RELEASES